What is Neurosense Therapeutics Ltd's earnings per share (EPS)?

Neurosense Therapeutics Ltd (NRSNW) reported diluted earnings per share of $-0.44 for fiscal year 2025. This represents a 18.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Neurosense Therapeutics Ltd Financials

NRSNW

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Neurosense Therapeutics Ltd (NRSNW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 14/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Neurosense Therapeutics Ltd's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Neurosense Therapeutics Ltd carries a low D/E ratio of -1.66, meaning only $-1.66 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 86/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Neurosense Therapeutics Ltd's current ratio of 0.31 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-0.44

YoY+18.5%

Neurosense Therapeutics Ltd earned $-0.44 per diluted share (EPS) in fiscal year 2025. This represents an increase of 18.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$166K

YoY-95.1%

Neurosense Therapeutics Ltd held $166K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

33M

YoY+40.2%

Neurosense Therapeutics Ltd had 33M shares outstanding in fiscal year 2025. This represents an increase of 40.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$8K

YoY+166.7%

Neurosense Therapeutics Ltd invested $8K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 166.7% from the prior year.

NRSNW Income Statement

Metric	FY25	FY24	FY23	FY22	FY21
Revenue	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$5.7M-21.7%	$7.3M+30.2%	$5.6M+300.8%	$1.4M
SG&A Expenses	$4.9M+15.6%	$4.2M-12.0%	$4.8M-3.9%	$5.0M+212.2%	$1.6M
Operating Income	N/A	-$9.9M+17.8%	-$12.0M-14.2%	-$10.6M-253.6%	-$3.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$10.2M-1.0%	-$10.1M+3.7%	-$10.5M-225.8%	-$3.2M
EPS (Diluted)	$-0.44+18.5%	$-0.54+27.0%	$-0.74+18.7%	$-0.91-75.0%	$-0.52

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q4'22
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

NRSNW Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21
Total Assets	$1.0M-77.5%	$4.6M+43.6%	$3.2M-58.7%	$7.7M	N/A
Current Assets	$778K-82.3%	$4.4M+51.0%	$2.9M-60.5%	$7.4M	N/A
Cash & Equivalents	$166K-95.1%	$3.4M+28.0%	$2.6M-25.5%	$3.5M-68.0%	$11.1M
Inventory	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.6M+29.9%	$2.0M-59.7%	$4.9M+164.0%	$1.9M	N/A
Current Liabilities	$2.5M+26.3%	$2.0M-42.4%	$3.5M+100.4%	$1.7M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.6M-160.4%	$2.6M+246.8%	-$1.8M-130.1%	$5.8M-46.1%	$10.8M
Retained Earnings	-$47.8M-30.3%	-$36.7M-40.3%	-$26.1M-63.1%	-$16.0M	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q4'22
Total Assets	$1.0M-39.0%	$1.7M-63.2%	$4.6M+148.5%	$1.8M-42.2%	$3.2M-58.7%	$7.7M
Current Assets	$778K-50.0%	$1.6M-64.7%	$4.4M+171.9%	$1.6M-44.5%	$2.9M-60.5%	$7.4M
Cash & Equivalents	$166K-75.1%	$666K-80.3%	$3.4M+179.6%	$1.2M-54.2%	$2.6M-25.5%	$3.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.6M+17.5%	$2.2M+10.6%	$2.0M-43.8%	$3.5M-28.3%	$4.9M+164.0%	$1.9M
Current Liabilities	$2.5M+14.2%	$2.2M+10.6%	$2.0M-43.2%	$3.5M+1.4%	$3.5M+100.4%	$1.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.6M-200.6%	-$519K-120.1%	$2.6M+251.7%	-$1.7M+3.2%	-$1.8M-130.1%	$5.8M
Retained Earnings	-$47.8M-15.5%	-$41.4M-12.8%	-$36.7M-13.2%	-$32.4M-24.0%	-$26.1M-63.1%	-$16.0M

NRSNW Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	N/A	-$10.1M-21.3%	-$8.4M-9.7%	-$7.6M-394.9%	-$1.5M
Capital Expenditures	$8K+166.7%	$3K-89.7%	$29K-58.6%	$70K+311.8%	$17K
Free Cash Flow	N/A	-$10.1M-20.9%	-$8.4M-9.1%	-$7.7M-394.0%	-$1.6M
Investing Cash Flow	-$8K-900.0%	$1K-100.0%	$3.5M+196.6%	-$3.6M-21017.6%	-$17K
Financing Cash Flow	$4.4M-59.4%	$10.9M+174.5%	$4.0M+5.3%	$3.8M-68.3%	$11.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q4'22
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

NRSNW Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-395.3%	N/A	-179.5%-149.8pp	-29.7%
Return on Assets	N/A	-223.2%+94.2pp	-317.3%-181.4pp	-136.0%	N/A
Current Ratio	0.31-1.9	2.21+1.4	0.84-3.4	4.28	N/A
Debt-to-Equity	-1.66-2.4	0.77+3.6	-2.81-3.1	0.32	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q4'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	0.31-0.4	0.71-1.5	2.21+1.7	0.46-0.4	0.84-3.4	4.28
Debt-to-Equity	-1.66+2.6	-4.24-5.0	0.77+2.9	-2.08+0.7	-2.81-3.1	0.32
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$1.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.31), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

What are Neurosense Therapeutics Ltd's total assets?

Neurosense Therapeutics Ltd (NRSNW) had $1.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Neurosense Therapeutics Ltd's capital expenditures?

Neurosense Therapeutics Ltd (NRSNW) invested $8K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Neurosense Therapeutics Ltd have outstanding?

Neurosense Therapeutics Ltd (NRSNW) had 33M shares outstanding as of fiscal year 2025.

What is Neurosense Therapeutics Ltd's current ratio?

Neurosense Therapeutics Ltd (NRSNW) had a current ratio of 0.31 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Neurosense Therapeutics Ltd's debt-to-equity ratio?

Neurosense Therapeutics Ltd (NRSNW) had a debt-to-equity ratio of -1.66 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is Neurosense Therapeutics Ltd's debt-to-equity ratio negative or unusual?

Neurosense Therapeutics Ltd (NRSNW) has negative shareholder equity of -$1.6M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Neurosense Therapeutics Ltd?

Neurosense Therapeutics Ltd (NRSNW) scores 14 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.